SVRA

Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company founded and headquartered in Austin, Texas, that went public in April 2017. The company specializes in developing treatments for rare respiratory diseases, with its primary focus on conditions that affect the lungs and breathing systems. As a clinical-stage company, Savara is still in the research and development phase, working to bring its experimental treatments through various stages of clinical trials before they can be approved for commercial use by regulatory authorities like the FDA.